Latest Intellectual Property News

Amplia Therapeutics reported encouraging mature data from its ACCENT trial, initiated a Phase 2b pancreatic cancer study, launched an ovarian cancer trial, and refreshed its board leadership while maintaining a solid cash balance of A$24 million.

Carnegie Clean Energy has made substantial progress on its ACHIEVE Programme, including module assembly and regulatory approvals for ocean deployment in Spain, supported by a $2.5 million private placement to fund commercial expansion.

Vection Technologies has turned a corner with its first full-year positive operating cash flow, underpinned by $41.5 million in customer receipts and over $17 million in new orders announced around the year-end.

Wide Open Agriculture (ASX: WOA) is executing a major strategic pivot by closing its German production site and transitioning to a capital-light contract manufacturing model to improve economics and scale lupin protein production.

Argent BioPharma has eliminated US$5.5 million in secured debt through a global licensing agreement for its CannEpil® epilepsy therapy, while completing a key acquisition and advancing clinical trials in veterinary therapeutics.

Reward Minerals (ASX:RWD) reported strong gold and copper assay results from its Mountain Pond Project in Newfoundland, with preparations underway for maiden drilling in the September quarter. The company also advanced its potash processing technology and ongoing discussions for the Beyondie Potash Plant in Western Australia.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

Firebrick Pharma expanded its patent portfolio with grants in Canada and New Zealand while achieving 43% sales growth in FY26 despite steady operating expenses. The company is advancing Nasodine's commercial rollout across Southeast Asia and the US.

BlinkLab has bolstered its war chest with a A$17.5 million placement, secured a foundational US patent valid through 2041, and made significant progress in its FDA autism diagnostic trial and European ADHD study.

Nyrada has dosed the first patient in its Phase IIa trial of Xolatryp targeting heart attack recovery, while strengthening its cash reserves and receiving a US patent allowance for its lead drug.

Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.

Great Bear Exploration (ASX:GBL) has secured $6.5 million to back its acquisition of the Great Bear Project in Canada, gearing up for a two-year exploration campaign starting August 2026. The company also reshapes its focus by restructuring HCD Technologies rights.